Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
A ArdizzoniJ Verweij

Abstract

To assess activity and toxicity of topotecan in previously treated small-cell lung cancer (SCLC) patients. Patients with measurable SCLC, progressive after one first-line regimen, were eligible for the study. Two groups of patients were selected: (1) patients who failed first-line treatment < or = 3 months from chemotherapy discontinuation (refractory group); and (2) patients who responded to first-line treatment and progressed greater than 3 months after chemotherapy discontinuation (sensitive group). Topotecan was administered as a 30-minute daily infusion at a dose of 1.5 mg/m2 for 5 consecutive days, every 3 weeks. One hundred one patients were entered onto the study and 403 courses were administered. Ninety-two patients (47 refractory and 45 sensitive) were eligible and assessable for response. Among refractory patients, there were two partial responses (PRs) and one complete response (CR), for an overall response rate of 6.4% (95% confidence interval [CI], 1.3% to 17.6%), whereas in the sensitive group, there were 11 PRs and six CRs, for an overall response rate of 37.8% (95% CI, 23.8% to 53.5%). Overall median duration of response was 7.6 months. Median survival was 5.4 months; median survival of refractory patients was ...Continue Reading

Citations

Jun 12, 1998·Journal of Surgical Oncology·M L Salgaller, P A Lodge
Nov 9, 2000·Medical and Pediatric Oncology·B H KushnerN K Cheung
Oct 24, 2000·Drugs & Aging·R J Stephens, D H Johnson
Mar 20, 2001·Current Oncology Reports·Y Ohe, N Saijo
Apr 17, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gregory A MastersUNKNOWN Eastern Cooperative Oncology Group
Jan 23, 2004·The New England Journal of Medicine·Alexander Spira, David S Ettinger
Nov 18, 2006·Cancer Chemotherapy and Pharmacology·G P StathopoulosD Skarlos
Feb 1, 2007·Anti-cancer Drugs·Hatem A Azim, Apar Kishor Ganti
Oct 11, 2007·Acta Oncologica·Daniel MorgenszternRamaswamy Govindan
Feb 9, 2008·Cancer Chemotherapy and Pharmacology·Se Hoon ParkJae Hoon Lee
Feb 20, 2009·International Journal of Clinical Oncology·Tsuneo ShimokawaAkihiko Gemma
Aug 22, 2009·Expert Opinion on Emerging Drugs·Giulio Metro, Federico Cappuzzo
Jul 16, 2010·Current Oncology Reports·Estelamari Rodriguez, Rogerio C Lilenbaum
Apr 20, 2010·Expert Review of Anticancer Therapy·Lucyna Kepka, Marta Olszyna-Serementa
Oct 13, 2010·Japanese Journal of Clinical Oncology·Yukito IchinoseKoshiro Watanabe
Jan 18, 2011·Der Internist·M Reck, S Bohnet
Jan 24, 2013·International Journal of Molecular Sciences·Maria CaffoFrancesco Tomasello
Jun 26, 2013·Journal of Asian Natural Products Research·Jian LvPeng Yu
Nov 12, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Joachim von PawelMarkus F Renschler
May 24, 2017·Nature Reviews. Clinical Oncology·Joshua K SabariCharles M Rudin
Sep 1, 2014·Therapeutic Innovation & Regulatory Science·Takashi OguraTsutomu Urano
Apr 14, 2020·Cell Biology International·Yuwen WangShi Xu
Mar 18, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J von PawelR Gralla
Nov 4, 2000·Expert Opinion on Investigational Drugs·F P Worden, G P Kalemkerian
Dec 18, 2001·British Journal of Cancer·L S HofstraP H Willemse
Jan 7, 1999·The Annals of Pharmacotherapy·R J Cersosimo
Feb 16, 2005·Expert Opinion on Drug Safety·Karen Seiter
Apr 13, 2005·Annals of Saudi Medicine·Irfan Maghfoor, Michael C Perry
May 4, 2004·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Hannes HentzeAlbrecht Wendel
Mar 18, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John R EckardtHazel B Breitz
Dec 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sayaka OnodaUNKNOWN Thoracic Oncology Research Group Study 0301
Dec 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mary E R O'BrienTheresa Crofts

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
A ArdizzoniGiuseppe giaccone European organization for research and treatment of cancer (EORTC) lung cancer group
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
R Perez-SolerW K Hong
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
J H SchillerD Johnson
© 2021 Meta ULC. All rights reserved